AC Immune announced it has entered into a Research and Development collaboration with Biogen comprising two radiopharmaceutical diagnostic programs in neurodegenerative diseases. The companies will further research, develop and clinically validate an alpha-synuclein PET radioligand that will be used as an imaging biomarker for Parkinson’s disease and related synucleinopathies to enable the clinical development of new disease-modifying therapies. In parallel, the partners will pursue a new research program to identify and develop novel PET radioligands for TDP-43, a recently identified target of growing interest in the pathogenesis of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease)…
Source: AC Immune